Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2025
This study aims to evaluate the efficacy and safety of Ripertamab in combination with Eltrombopag compared to Eltrombopag alone for patients with Primary Immune Thrombocytopenia (ITP) who have not responded to or have relapsed after first-line steroid therapy. Participants will be randomly assigned to one of two treatment groups and followed for 52 weeks to assess response rates and safety.
Epistemonikos ID: d7f13321b857ba950c25ff986865827d9a1fa270
First added on: Mar 27, 2025